The study assessed how MLIF affected human CD4+ T cells' intrinsic and extrinsic apoptotic pathways. For 24 hours, cells were either cultured in RPMI-1640 media alone (control), or in RPMI medium with actinomycin D, MLIF, PMA, or any combination of the four. According to annexin V/propidium iodide-stained cells, cells treated with MLIF or PMA + MLIF did not significantly differ from control cells in medium during early apoptosis; in contrast, cells treated with PMA or PMA + MLIF displayed significant differences from the control during delayed apoptosis. Cells treated with PMA and PMA + MLIF showed a considerable rise in cytochrome c and caspase 3 levels when compared to the control, showing that this ineffective activation of cell death is governed by the intrinsic route of apoptosis. In comparison to control cells, MLIF-treated cells did not significantly differ in their levels of cytochrome c or caspase 3. The lack of Fas receptor identification in cell culture in response to any of the treatments used suggests that the extrinsic mechanism of apoptosis is not activated. When treated to MLIF, human CD4+ T lymphocytes may not undergo apoptosis; nevertheless, PMA and MLIF may also affect the minor quantities of cell death seen during the late apoptosis phase. MLIF is an intriguing candidate for possible clinical uses because of its small size and ability to act as a natural, biological anti-inflammatory chemical produced in Entamoeba histolytica axenic cultures.
Author(s) Details:
Sara Rojas-Dotor,
Unidad de Investigación Médica en Inmunología, Hospital de Pediatría, Centro Médico Nacional Siglo XXI Instituto Mexicano del Seguro Social (IMSS), México City, México.
Marco Julio Sánchez Rojas,
Facultad de Medicina, Universidad Nacional Autónoma de México (UNAM), México City, México.
Please see the link here: https://stm.bookpi.org/CAPR-V6/article/view/8094
No comments:
Post a Comment